International outlets are interested in Egypt turning into a global affordable destination for those seeking Hepatitis C treatment. Egypt has been producing the treatment Sovaldi since 2015 since 2015 under a government-sponsored initiative that has lowered the price of a full course of treatment to around USD 83 from around USD 84,000, the website claims. The treatment was developed by the US-based Gilead in 2013, but under the Tour N’ Cure initiative, Egypt’s government is able to offer the treatment to patients for about 8% of its cost, which means that patients from all countries come to Egypt for treatment, campaign director Mostafa El Sayed says.
More from Enterprise
The digital EGP won’t look different at checkout — but it will work nothing like InstaPay
Every instant payment today depends on your bank or telco.…
Granite is about to test whether Egypt’s funds still need administrators
The asset manager and blockchain builder Tarmiiz have entered the…
Egypt is fixing how deals get executed, but what pushes investors offshore runs deeper than the reforms on the table
Investment Ministry and a Senate committee are both moving to…
Egyptian-UK fintech Zeal raises USD 10 mn to back expansion plans
The London-based, Egyptian-founded fintech is preparing to activate its loyalty…